China Monogenic Diabetes Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorTianjin Medical University General Hospital
About this trial
This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to:
Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution
Participants will:
* Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age
Body mass index (BMI) at diagnosis 28 kg/m²
Negative glutamic acid decarboxylase antibody (GAD-Ab)
Disqualifiers
Secondary diabetes
Active malignancy or history of malignant tumor within the past 5 years
Trial population
Diabetes patients who completed gene test and necessary further tests and voluntary to be followed up will be included.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No Interventions
Other interventionNo Interventions
Treatment groups
5,000 Participants
are divided into 1 treatment groupGroup A: Monogenic Diabetes1 intervention
Trial outcomes
Primary outcomes
1
Screened and confirmed monogenic diabetes
Screened and confirmed through genetic testing according to established diagnostic criteria for monogenic forms of diabetes (including MODY, neonatal diabetes, and other monogenic subtypes)
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov